AD Pipeline Watch: Amgen, Kyowa Kirin’s Anti-OX40 Candidate Meets Endpoints in AD Trial March 10, 2025
Unpacking the Latest Results From The ADORING 3 Study of Tapinarof in AD With Linda Stein Gold, MD March 8, 2025
Taking a Deep Dive Into Three-year Data on Lebrikizumab in AD With Raj Chovatiya, MD, PhD March 7, 2025
Survey: Chronic Hand Eczema Is Widely Misunderstood and Inadequately Managed by Many Derms March 5, 2025
Apogee Pipeline Update: Positive Interim Phase 1 Results From the APG990 Healthy Volunteer Trial Unlock Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) March 3, 2025
